Guangdong Biolight Meditech (300246) Fundamentals 2026 — Revenue Analysis | SniperIQ
Guangdong Biolight Meditech (300246) is a CN-listed Healthcare company in Medical - Devices with a market capitalization of ¥4.2B, trading at ¥16.06 on the SHZ. This SniperIQ fundamentals page covers Guangdong Biolight Meditech's valuation, profitability (net margin -8.4%), revenue (¥1.1B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Guangdong Biolight Meditech's market cap?
Guangdong Biolight Meditech (300246) has a market capitalization of approximately ¥4.2B, trading at ¥16.06 on the SHZ. Market cap moves with the live share price.
What is Guangdong Biolight Meditech's P/E ratio?
Guangdong Biolight Meditech's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 3.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Guangdong Biolight Meditech?
Guangdong Biolight Meditech runs a net profit margin of -8.4%, a gross margin of 24.9%, and an operating margin of -7.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Guangdong Biolight Meditech generate?
Guangdong Biolight Meditech reported revenue of ¥1.1B for fiscal year 2025, with net income of -¥69M and earnings per share (EPS) of -0.26. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Guangdong Biolight Meditech pay a dividend?
Guangdong Biolight Meditech offers a trailing dividend yield of about 0.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Guangdong Biolight Meditech financially healthy?
Guangdong Biolight Meditech carries a debt-to-equity ratio of 0.67x and a current ratio of 1.46x, with a market beta of 1.18. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Guangdong Biolight Meditech a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Guangdong Biolight Meditech (300246) the key facts are: market cap ¥4.2B, revenue ¥1.1B, 52-week range 7.67-21.98. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Guangdong Biolight Meditech's full fundamentals live
Get Guangdong Biolight Meditech's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.